Education
About Us
Working with TipRanks
Follow Us
Evelo Biosciences Inc (EVLO)
OTHER OTC:EVLO
EVLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume66.00
Average Volume (3M)44.00
Market Cap
$9.49K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta25.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.35
Shares Outstanding18,982,838
10 Day Avg. Volume44
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evelo Biosciences News
EVLO FAQ
What was Evelo Biosciences Inc’s price range in the past 12 months?
Evelo Biosciences Inc lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is Evelo Biosciences Inc’s market cap?
Evelo Biosciences Inc’s market cap is $9.49K.
When is Evelo Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evelo Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Evelo Biosciences Inc overvalued?
According to Wall Street analysts Evelo Biosciences Inc’s price is currently Overvalued.
Does Evelo Biosciences Inc pay dividends?
Evelo Biosciences Inc does not currently pay dividends.
What is Evelo Biosciences Inc’s EPS estimate?
Evelo Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evelo Biosciences Inc have?
Evelo Biosciences Inc has 18,982,838 shares outstanding.
What happened to Evelo Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evelo Biosciences Inc?
Currently, no hedge funds are holding shares in EVLO
Company Description
Evelo Biosciences Inc
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
―
Insiders
―
Mutual Funds
51.91% Other Institutional Investors
48.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---